ஜேம்ஸ் பான் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜேம்ஸ் பான். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜேம்ஸ் பான் Today - Breaking & Trending Today

Exacis Biotherapeutics Presents Data on its Stealth mRNA-Engineered NK-cell Platform at American Society of Gene & Cell Therapy Annual Meeting


Share this article
Share this article
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/  Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis cell engineering strategy is designed to allow its ExaNK™ cells to evade surveillance by the patient s immune system, thus rendering the cells rejection resistant, or  stealth , to enable increased persistence in patients without genotoxic pre-conditioning. ....

United Kingdom , United States , James Pan , Exacis Biotherapeutics , American Society Of Gene Cell Therapy , Exacis Biotherapeutics Inc , American Society , Cell Therapy , Gregory Fiore , Efficiency Generation , Biallelic Gene Knockout , Factor Bioscience , Natural Killer , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , ஜேம்ஸ் பான் , அமெரிக்கன் சமூகம் ஆஃப் கீந் செல் சிகிச்சை , அமெரிக்கன் சமூகம் , செல் சிகிச்சை , கிரெகொரி ஃபியரி , காரணி உயிர் அறிவியல் , இயற்கை கில்லர் ,

Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies


Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis  next generation approach avoids use of DNA and viruses by using mRNA. The technologies will be used for generating iPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-T™ or ExaCAR-NK™ cells. ....

United Kingdom , Eric Westin , Gregory Fiore , Mark Corrigan , Matthew Angel , Christopher Rohde , James Pan , Exacis Biotherapeutics , Gunnar Kaufmann , Prnewswire Exacis Biotherapeutics Inc , Factor Co , Factor Bioscience , Scientific Advisory Board , Chief Executive , Chief Business , Factor Co Founder Christopher Rohde , Exaci Board , Board Chairman Corrigan , ஒன்றுபட்டது கிஂக்டம் , எரிக் வெஸ்டின் , கிரெகொரி ஃபியரி , குறி கோரிகன் , மேத்யூ தேவதை , கிறிஸ்டோபர் ரோட் , ஜேம்ஸ் பான் , கன்னர் காஃப்மந் ,